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BurdeN of INflueNza B IN 9 euroPeaN CouNtrIes: a lIterature revIew
Tafalla M.1, Buijssen M.2, Geets R.1, Vonk Noordegraaf M.2
1GalxoSmitKline Vaccines, Wavre, Belgium, 2Pallas, AE Rotterdam, The Netherlands
Objectives: Seasonal influenza causes substantial public health burden world-
wide. Currently, trivalent vaccines containing two strains of influenza A and one of 
the two circulating influenza B strain lineages (Yamagata and Victoria) are mostly 
used. In recent years, the co-circulation of these two influenza B lineages has cre-
ated some mismatch with the recommended vaccine. The objective is to summa-
rize the epidemiology, burden and seasonality of influenza B in nine European 
countries: Switzerland, Austria, Belgium, Luxembourg, Finland, Greece, Czech 
Republic, Slovakia and Estonia. MethOds: Comprehensive review of PubMed and 
Cochrane library as of the year 2003. Additionally, a search in other data sources, 
such as websites of WHO, ECDC and national surveillance for influenza was per-
formed. Results: 10 peer-reviewed articles were included: 10 reported on epi-
demiology, 6 on disease burden and 3 on circulating strains. From grey literature, 
additional data on influenza B circulating lineages and vaccine were provided. 
Incidence data were only available for Finland. No information was found on inci-
dence or prevalence of influenza B for any other country. Articles lacked a defined 
catchment population and only proportions of influenza B among a specified popu-
lation or surveillance samples could be obtained. Though Influenza B-associated 
hospitalization rate among children < 1 year was reported in one article for Finland, 
no additional information was found on influenza B-associated hospitalizations or 
outpatient visits or emergency room for any of the other countries. Information on 
other outcome measures for disease severity was scarce as well. Seasonal variation 
and circulating strains were scarcely presented in peer-reviewed literature; some 
data were found in grey data sources though. cOnclusiOns: While surveillance 
systems have identified the co-circulation of 2 influenza B lineages and vaccine 
mismatch, there is still a low awareness about its burden probably due to the lack 
of appropriately designed studies in the assessed countries.
PIN16
PoteNtIal ePIdemICs of drugs resIstaNt BaCterIa IN Poverty 
strICkeN CouNtrIes lIke PakIstaN
Hussain T
National University of Sciences and Technology, Islamabad, Pakistan
Objectives: Antibiotics are the only promising drugs used to control bacterial 
diseases but their inappropriate use has rendered bacteria resistant. Bacteria have 
been found resistant to all classes of antibiotics including the last line antibiotics 
carbapenems. These multidrug resistant bacteria are a constant threat to human 
health. The aim of this study was to check for pathogenic contaminants in drink-
ing water samples across Pakistan check their drug resistant level too. MethOds: 
Drinking water samples were collected from different regions across Pakistan and 
microorganisms present in these samples were identified. Kirby-Bauer disc diffu-
sion tests were used to check the pattern of antibiotic resistance. Interpretation 
was done according to Clinical and Laboratory Standards Institute (CLSI) recom-
mendations. Results: Almost all of the water samples collected were contami-
nated with bacteria or protozoans. All of the contaminated samples had Escherichia 
coli, while many of them had Cryptosporidium spp and Giardia spp. Escherichia 
coli isolates were found resistant to many groups of antibiotics including carbap-
enems (17%). Antibiotics were not helpful against Cryptosporidium and Giardia 
spp. cOnclusiOns: Because of the unhygienic living style and poverty, the threat 
of these resistant bacteria is increasing, and since carbapenems are drugs of the last 
resort such a high prevalence of resistant bacteria in drinking water is an alarming 
threat and holds the potential of future outbreaks.
PIN17
dIsaBIlIty-adjusted lIfe years (dalys) as a ComPosIte measure to 
exPress the BurdeN of tICk-BorNe eNCePhalItIs (tBe) IN sloveNIa
Šmit R., Postma M.J.
University of Groningen, Groningen, The Netherlands
Objectives: TBE is a serious central nervous system disease, which may lead to 
permanent neurological sequelae or even death. TBE is becoming a high burden in 
many parts of Europe, Asian Russia, Siberia, Asian former USSR and Far East. The 
burden is usually expressed by only the incidence or death. DALYs give a composite 
assessment of TBEʼs burden while only the incidence or deaths does not really indi-
cate the real impact on burden. The purpose of the present study is to estimate the 
burdens from the population- and individual perspectives for TBE in Slovenia, meas-
ured in DALYs and evaluate the possibilities of reducing this burden. MethOds: 
The burden of TBE in Slovenia is estimated by using the updated DALYs’ method-
ology first introduced by Murray and co-workers in the Global Burden of Disease 
(GBD) project. Adjustment to correct for under-reporting and under-ascertainment 
is applied. Calculations were based on the health outcomes of the natural course of 
TBE. Results: From the population perspective DALYs amount to 3,450 while from 
the individual perspective they amount to 3.1. The neurological sequelae have the 
largest impact on the overall DALYs measurement for TBE. cOnclusiOns: Rising 
awareness and increasing vaccination coverage for TBE is proposed for the whole 
population to reduce the burden and provide health benefits to the population as 
a whole in Slovenia.
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meta-regressIoN oN euroPeaN zoster INCIdeNCe
Terlinden A.1, Varghese L.2, Curran D.2
1Navigha, Tervuren, Belgium, 2GlaxoSmithKline Vaccines, Wavre, Belgium
Objectives: Nowadays populating a decision-making model with input data has 
become a cumbersome process due to the numerous choices of data sources. To 
tackle this issue, regulatory and re-imbursement agencies encourage “evidence 
synthesis for decision making”. To this end meta-analysis methods are gaining 
renewed interest as a means of summarizing results of multiple scientific papers 
Objectives: To describe long term outcomes of one of the first cohort of HIV 
positive patients started on antiretroviral treatment (ART) in Sub-Saharan 
Africa. MethOds: We report 10-years outcomes including mortality, retention, 
CD4-count response, viral suppression (achievement of viral load (VL) < 400 copies/
ml by month-6) and failure (2 consecutive VL> 400 copies/ml or 1 VL> 5000 cop-
ies/ml-as per WHO guidelines), drug substitution from a prospective cohort of 559 
patients initiating ART between April 2004-April 2005 and followed up for 10-years 
in Kampala, Uganda. Results: Of 559 patients, 70% were female, median age (IQR) 
was 38 (33–44) years, median CD4-count (IQR) 98 (21–163) cell/µL, VL (log10) 5.4 
(5.0–5.8) copies/ml. 414 (74%) were started on stavudine+lamivudine+nevirapine, 
145 (26%) on zidovudine+lamivudine+efavirenz. After 10 years 361 (65%) patients 
were still in the study; 123 (22%) had died; 30 (5%) were lost to follow-up; 27 (5%) 
transferred; 18 (3%) withdrew consent. Mortality was high in the first year (80/123, 
65%) and substantially reduced over time. The median gain in CD4-count (IQR) was 
of 477 (199-738) cell/µL and 321 (57.4%) reached 400 cells/µL (lower limit of normal 
CD4-count in Ugandans). 82% (388/473) with available VL at month-6 achieved viral 
suppression (VL< 400 copies/ml), and of those 44 (9.1%) experienced viral failure 
after a median time (IQR) of 45 (17-69) months on ART. 73 (13.1%) switched to second 
line regimen due to ART failure. We observed 184 drug substitutions; before the 
new WHO guidelines release (2009) 52% of these (74/142) were due to toxicity as 
compared to only 17% (7/40) after 2009. cOnclusiOns: High rate of early mortality 
due to advanced disease at presentation resulted in suboptimal retention; however 
good treatment response and first line durability was achieved in patients retained 
on treatment. Rates of drug substitution were high particularly up to 2009 due to 
the use of less tolerated regimes in this period.
PIN13
traNsItIoNal ClINIC utIlIzatIoN aNd geNeral well BeINg of ugaNdaN 
youNg adults lIvINg wIth hIv/aIds
Nyabigambo A.1, Muliira J.K.2, Kambugu A.3
1Global Health Economics Limited, KAMPALA, Uganda, 2Sultan Qaboos University, Muscat, 
Uganda, 3Makerere University, Infectious Diseases Institute, KAMPALA, Uganda
Objectives: To determine the relationship between utilization of the HIV transi-
tion clinic utilization at the Infectious Diseases Institute (HTC-IDI) and general 
wellbeing of young adults living with HIV/AIDS (YALHA). MethOds: This cross 
sectional study was conducted between March and May 2012 at the HTC-IDI in 
Kampala, Uganda. The study recruited 379 YALHA who were between the ages of 
15-24 years. HTC-IDI utilization was categorized into two levels; regular (kept all 
the appointments visits) and irregular (missed one or more appointments visits) 
utilization. The general well-being of YALHA was measured using the 18-item 
general wellbeing schedule (GWS-18). The responses to each item of the GWS-
18 were aggregated and the scores were converted to a 0-100 point scale (100= 
Highest general wellbeing status). Factor analysis was used to systematically group 
the GWS-18 questionnaire. Unpaired t-test, and multivariable logistic regression 
were used to determine the association between utilization and general wellbe-
ing. Results: The mean (SD) age was 22.5±2.0 years with an age range of 15 to 24 
years and the mean (SD) CD4 cell count was 402.3±293.3 with a range of 1-2603/µl, 
231 (60.9%) were currently on ART. Of the 379 YALHA, only 32.4% regularly utilized 
the HTC. The GWS-18 tool was highly acceptable, easily administered and was 
systematically grouped into two factors (anxiety and self-control). The overall scale 
demonstrated good internal consistency with Cronbach’s alpha of 0.82. There was 
no statistically significant association between general wellbeing and utilization of 
the HIV transition clinic. cOnclusiOns: The current study found no significant 
relationship between HTC-IDI utilization and the general well being of YALHA. 
Future studies should use longitudinal designs to ensure long-term follow up of 
the YALHA using disease specific generic tools since well-being has a tendency 
of fluctuating depending on emotional and physical feelings, which may not be 
captured in a cross sectional study.
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the ePIdemIologIC BurdeN of hePatItIs C vIrus INfeCtIoN IN egyPt
Szabo S.M.1, Juarez-Garcia A.2, Levy A.R.1, Donato B.M.K.3
1ICON Epidemiology, Vancouver, BC, Canada, 2Bristol-Myers Squibb Company, Mexico City, 
Mexico, 3Bristol-Myers Squibb Company, Wallingford, CT, USA
Objectives: Chronic infection with hepatitis C virus (HCV) is a major public 
health concern in Egypt. Prevalence data exist, but methods to estimate the epi-
demiologic burden have varied and there has been no systematic approach to 
synthesize these data. The objective of this study is to synthesize published reports 
of prevalence and estimate the total number of HCV cases in Egypt. MethOds: A 
systematic search was implemented by two reviewers in the EMBASE, Medline, and 
Cochrane databases, to identify and extract data from population-based studies 
of the epidemiologic burden of HCV in Egypt. Estimates based on laboratory-
confirmed HCV infection, published between January 1, 1995 and May 13, 2014, 
were included. Published data were supplemented with data from the National 
Blood Transfusion Center (NBTC) in Egypt. 2014 population estimates were used 
to project the number of persons infected based on synthesized prevalence esti-
mates. Results: From 630 abstracts, 23 studies were identified. The population-
based Demographic and Health Survey (DHS) estimated the prevalence of active 
infection at 9.8% and overall HCV infection at 14.9%; which is likely an underesti-
mate of e the total population affected since DHS was restricted to people 15 to 55 
years of age. Estimates from blood donors from the NBTC were ~7.5%, supporting 
the low estimate from DHS. Population-based estimates from studies conducted 
in areas of high infectivity were as high as 40 to 50% HCV prevalence. Based on 
a prevalence estimate of 15% (12-18%), approximately 13 million (10-16 million) 
people are infected with HCV in Egypt. cOnclusiOns: Although estimates of the 
prevalence of HCV vary, the wealth of evidence suggests that there is an extensive 
epidemiologic burden in Egypt. With the availability of new therapies, decision-
makers and clinicians need accurate estimate of disease prevalence to assess the 
cost-benefit ratio of new HCV treatments.
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PIN21
Cost savINgs for the use of aNtIBaCterIal sutures IN sPaNIsh 
hosPItals. Budget ImPaCt model
Pobre M.A.1, Espallardo O.1, Alfonso J.L.2, Pinyol C.3
1Johnson & Johnson Medical, Madrid, Spain, 2University General Hospital Consortium Valencia, 
Valencia, Spain, 3INNOVA Strategic Consulting, Terrassa, Spain
Objectives: The surgical site infection (SSI) is the most often acquired hospital 
infection in Spain, about 19.4% of all nosocomial infections. The prevalence of this 
adverse event is 8.01%, generating high economic impact on hospital costs and 
undermining the quality of care. The risk of SSI has increased in recent years and 
infections have become more resistant to treatments. About 50% of SSIs are pre-
ventable, their costs are avoidable, and health technology can help avoiding them. 
The aim of this study is to analyze the economic impact that could represent the 
use of anti-bacterial sutures compared with conventional ones in Spanish hospi-
tals. MethOds: An interactive Excel model was developed using data obtained 
through a published literature review. The rate of reduction of SSI with antibacte-
rial suture is 30%. The incremental cost per patient with SSI is between € 9,657 and 
€ 10,112.63. Two scenarios were designed: 100% of surgeries with normal sutures and 
100% of surgeries with anti-bacterial sutures. A sensitivity analysis for the variables 
of greatest uncertainty was performed (cost per SSI). Results: The budget impact 
of the use of antibacterial sutures resulted in a 24% of cost savings related to the 
normal sutures. It represents savings of € 5.4M per year for an average Spanish 
hospital, and € 1,264M per year for the whole Spanish Health System. The results of 
the sensitivity analysis shows that even by changing the effectiveness of the suture 
and using the most unfavourable data found in the literature for the cost of an SSI, 
the use of the antibacterial suture still produces savings of 24% compared with the 
use of normal suture. cOnclusiOns: This budget impact analysis provides new 
evidence that reinforces the use of antibacterial sutures, because it may reduce 
the risk of SSI, the negative effects of its consequences and associated costs and 
significantly improving the quality of care for surgical patients in Spain.
PIN22
moNItorINg aNtIretrovIral theraPy IN ugaNda: Budget ImPaCt 
aNalysIs of two strategIes for vIral load moNItorINg versus 
ImmuNologIC moNItorINg
Castelnuovo B.1, Parkes Ratanshi R.1, Kakaire T.1, Sempa J.1, Reynolds S.2, Lamorde M.1
1Infectious Diseases Institute, Kampala, Uganda, 2NIH, Rakai, Uganda
Objectives: The 2013 WHO-guidelines recommend viral load (VL) monitoring plus 
CD4-count monitoring for patients on antiretroviral treatment (ART) in resource-
limited settings. We calculated the budget impact (BI) of VL monitoring strategies 
at the Infectious Diseases Institute (IDI), a large urban HIV program in Kampala, 
Uganda. MethOds: We calculated cost for the first 2 years of ART (drugs/tests/
staff) for three strategies: (1) Immunologic monitoring, standard of care (SOC): 
6-monthly CD4-count (2) New WHO-guidelines: SOC plus 6-monthly VL (3) A novel 
strategy: exclusive-VL (no CD4-counts after ART start), with VL at 3-months (to 
support adherence monitoring) and at 24 months. Patients with VL > 400copies/ml 
VL at 3-months will receive adherence counseling and repeat VL at 6-months. All 
costs are current actual costs at IDI and presented as 2012 USD ($): CD4-count= $9; 
VL= $65; first-line patients $206/year in year-1 and $272/year in year-2; second-line 
patients= $1381/year. For each strategy, rates of switch to second-line were estimated 
using IDI clinic data (1) SOC: 27%, 29%, 32% at 6, 12, 18 months (2) WHO-guidelines: 
7.3%, 10.8%, 13.8% at 6, 12, 18 months (3) Exclusive-VL: 21% at 3 months, 8.3% at 
6 months. Results: The cost per patient for the first 2 years of ART and BI of VL 
monitoring are (1) SOC: $572 (2) WHO- guidelines $897, BI $325 (3) Exclusive VL: 
$720, BI $148. Exclusive VL-monitoring results in a lower BI by supporting adher-
ence and averting ART failure. Increased cost with VL-monitoring is driven by more 
patients switching timely to second-line treatment with the cost of 2nd-line patients 
being 3.6 times higher for the new WHO-guidelines and 2.8 times higher for the 
exclusive-VL compared to SOC, rather than VL tests. cOnclusiOns: Implementing 
VL-monitoring strategies result in modest BI (26%-57%). Since switching timely to 
second-line benefits patients, similar programs should consider allocating resources 
to VL monitoring.
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Budget ImPaCt aNalysIs of 13-valeNt PNeumoCoCCal vaCCINe IN 
adult PoPulatIoN wIth ComorBIdItIes or ImmuNoComPromIsed from 
the PuBlIC Payer PersPeCtIve IN BrazIl
Ferreira C.N.1, Manfrin D.F.2, Rufino C.S.2, Gea Y.2, Haas L.C.3, Fernandes R.A.3
1Pfizer, Inc., New York, NY, USA, 2Pfizer, Inc., São Paulo, Brazil, 3ANOVA, Rio de Janeiro, Brazil
Objectives: Invasive pneumococcal disease (IPD) is a major public health chal-
lenge. This study aims to perform a budget impact analysis (BIA) of 13-valent 
pneumococcal conjugated vaccine (PCV13) in adults immunocompromised (IC) or 
with comorbidities (CM), from a public payer perspective in Brazil. MethOds: BIA 
using a Markov model framework estimated the incremental costs of a vaccination 
program over a 10 year period comparing PCV13 versus PPSV23 or no vaccination 
in adults ≥ 18 years with CM or IC. Population size was calculated from Brazilian 
Institute of Geography and Statistics (IBGE) projections for 2014-2023 period and 
prevalence of risk groups were extracted from literature. Efficacy data for PCV13 
and PPSV23 were based on published data. Direct medical costs obtained from the 
literature included hospital days, medical fees, outpatient visits, diagnostic tests, 
and drugs in Brazilian Real (BRL). PCV13 and PPSV23 costs per dose were 52.40BRL 
and 23.00BRL, respectively. Results: Eligible population consisted of 15,241,353 
(CM) and 1,305,794 (IC) patients, for the 10-year period. After vaccination with PCV13, 
111, 869 (CM) and 42,786 (IC) IPD cases were avoided versus PPSV23 and 110,208 (CM) 
and 40,224 (IC) IPD cases versus no vaccination. Incremental costs per patient were 
52.02BRL (CM), and 51.92BRL (IC), for vaccination with PCV13 versus non vaccination, 
leading to a budget impact of 793,005,843BRL (CM) and 67,805,835 (IC) for the 10-year 
into single estimates (with confidence intervals for sensitivity analyses). The pur-
pose of this study is to investigate various methodologies for synthesizing data 
used as inputs into an economic model, based on a systematic review of a specific 
disease incidence. MethOds: A random-effects meta-analysis was conducted to 
estimate herpes zoster incidence from a systematic literature review of herpes 
zoster incidence in Europe. Since incidence could potentially be explained by some 
study-specific characteristics meta-regression was investigated. The variable of 
interest was predicted based on the year of data collection, country, age-group and 
study design. As incidence (expressed as annual probability) is typically bounded 
by 0 and 1, a logistic function was used to model the link between the predicted 
variable and its predictors. Results: Statistical tests suggested that data from 
some studies were outliers and were thus inconsistent with the model. A significant 
positive correlation was observed between age and herpes zoster incidence. The 
model allows for trends in incidence data to be explored based on country, year of 
data collection, study design and age. cOnclusiOns: This project investigated 
the use of meta-analysis and meta-regression for synthesizing data coming from 
various sources identified through a systematic review. Limitations were identified 
for both approaches. However, the meta-regression analysis can be used to estimate 
the current incidence of a particular disease, for a specific age group and country. 
It could help health economists in populating models and, subsequently, decision 
makers in their evaluation and assessments.
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PredICtors for mortalIty amoNg humaN ImmuNodefICIeNCy vIrus 
INfeCted PatIeNts oN aNtIretrovIral theraPy
Sudheer A.P.1, Adusumilli P.K.2, Swamy V.1, Parthasarathi G.3, Mothi S.1
1Asha Kirana hospital, Mysore, India, 2JSS College of Pharmacy, Mysore, India, 3JSS University, 
Mysore, India
Objectives: Development of highly active antiretroviral treatment (ART) had 
revolutionized the care of Human Immunodeficiency virus (HIV) -infected patients 
and led to marked reductions in HIV-associated morbidity and mortality in many 
developed countries. Hence this study aimed to analyze the predictors for mortal-
ity among patients living with HIV and who are on Antiretroviral Therapy (ART) in 
a south Indian hospital. MethOds: A retrospective cohort study was conducted 
on 350 patients infected with HIV were admitted to Asha Kirana Hospital, Mysore-
South India for a period of three years. Patients who died in the hospital during 
the study period (n-80) were compared with patients who had survived (n-270). 
Both groups were matched for age and sex. Predictors for death were analyzed by 
chi-square test using bivariate regression in software SPSS version 21. Results: 
Predictors for death in this study were increasing age > 60 years (RR), (95% CI) 2.204, 
(1.15-4.21), CD4 count < 200 cells 2.14 (1.26-3.13), patients without opportunistic 
infections- 1.80 (1.23- 2.63), WHO stage IV 1.83 (1.25-2.67) and being on stavudine 
based ART 2.01 (1.44-2.81). Patients with under-weight 1.33 (0.88-1.99) also found 
be risk for mortality, but it is not statistically significant. Factors associated with 
survival benefit were female sex 0.81 (0.55-1.19), patients without ART toxicity 0.78 
(0.51-1.20) and being on Tenofovir based regimen 0.8 (0.79-0.96). cOnclusiOns: 
Predictors for mortality among HIV patients on ART were found to be patients age 
> 60 years, CD4 count < 200 cells, WHO stage IV, absence of opportunistic infec-
tions and patients on Stavudine therapy. The absence of opportunistic infections 
being a risk factor may be due to undiagnosed opportunistic infections due to 
limited diagnostic facility as in this study setting. Patients on Tenofovir having 
survival benefit support the 2013 WHO recommendation for Tenofovir being the 
preferred regimen.
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INItIal INaPProPrIate aNtIBIotIC theraPy IN hosPItalIzed  
PatIeNts wIth gram-NegatIve INfeCtIoNs: systematIC revIew aNd 
meta-aNalysIs
Raman G.1, Avendano E.2, Berger S.2, Menon V.3, Bartlett J.4
1Tufts University School of Medicine; Tufts Medical Center, Boston, MA, USA, 2Tufts Medical 
Center, Boston, MA, USA, 3Cubist Pharmaceuticals, Lexington, MA, USA, 4Johns Hopkins 
University School of Medicine, Baltimore, MD, USA
Objectives: The rapid global spread of multi-resistant bacteria and loss of anti-
biotic effectiveness increases the risk of initially inappropriate antibiotic therapy. 
We examined the effects of use of appropriate or inappropriate antibiotic ther-
apy on outcomes in Gram-negative infections. MethOds: We searched Medline, 
Cochrane Central, and Embase databases through March 2014 for English-language 
studies that quantified effects of use of appropriate or inappropriate antibiotic 
therapy on all-cause mortality, length of stay, hospital costs, treatment failure, or 
bacterial clearance in hospitalized patients with complicated urinary tract infec-
tion, complicated intra-abdominal infection, bacteremia and pneumonia due to 
Gram-negative pathogens. We screened citations in duplicate and resolved dif-
ferences by consensus. We used random effect models meta-analysis when at 
least 3 studies reported the same outcome. Results: Forty-five studies with 1895 
patients were eligible. The definition of initial appropriate antibiotic therapy varied 
across studies. In meta-analyses of unadjusted data, initial appropriate antibiotic 
therapy was associated with lower risk of mortality (26 studies, 3713 patients, odds 
ratio (OR) 0.52, 95% confidence interval (CI) 0.41– 0.66) and treatment failure (3 
studies, 283 patients, OR 0.22, 95% CI 0.14– 0.35). In meta-analyses of adjusted data, 
initial appropriate therapy was associated with lower risk of mortality (5 studies, 
1211 patients, OR 0.50,95% CI 0.25–1.00), and conversely, initial inappropriate ther-
apy increased risk of mortality (16 studies, 2493 patients, OR 3.30, 95% CI 2.42–4.49) 
and decreased bacterial clearance. There were insufficient data to evaluate the 
impact on resource utilization and economic outcomes. cOnclusiOns: Initial 
inappropriate therapy is associated with an increased risk of hospital mortality. 
The paucity of new and effective antibiotics to cover resistant Gram-negative 
pathogens increases the likelihood of initial inappropriate therapy and poses a 
serious threat to patient safety. Critical gaps include lack of information on the 
health and economic burden of resistance.
